NDM-Producing Enterobacterales: Applying Best Practices in Complex Clinical Scenarios
In this episode,Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections caused by NDM-producing Enterobacterales, including:
- Ambler classification of β-lactamases
- Mechanisms of resistance
- 2023 IDSA guidance recommendations
- The latest clinical data by antimicrobial regimen:
- Ceftazidime/avibactam and aztreonam
- Cefiderocol
- Investigational aztreonam/avibactam
- Clinical case of NDM-producing E. coli with pan-β-lactam resistance
Program Director:
Trevor Van Schooneveld, MD, FSHEA, FACP
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska
Faculty:
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland
Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine
Atlanta, Georgia
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at:
https://bit.ly/476v2wI
Link to full program:
https://bit.ly/40HyvPy
